UPC APP 4496/2025

—·EP4183412: RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Case details: Status
—
Action
Procedural application
Category
Other Procedural
Parties: Claimants
GlaxoSmithKline Biologicals SA
Reps: Oliver Jan Jüngst (Bird & Bird LLP); Luca Brons (Bird & Bird LLP)
Respondents
Pfizer Europe MA EEIG
Pfizer Manufacturing Belgium NV
Pfizer Pharma GmbH
Pfizer Corporation Austria GmbH
Pfizer S.A.
Pfizer Aps
Pfizer Oy
Pfizer SAS
Pfizer S.r.l.
Pfizer B.V.
Laboratórios Pfizer, Lda.
Pfizer AB
Pfizer Luxembourg S.a.r.l.
Pfizer Service Company S.R.L.
Reps: Gareth Williams (Marks & Clerk LLP); Claudia Milbradt (Clifford Chance); Tobias J. Hessel (Clifford Chance)
Division: Dusseldorf LD
Judges: Ronny Thomas · Presiding judge
Jule Schumacher · Legally qualified judge and judge-rapporteur
Andrea Postiglione · Legally qualified judge
Technology: Biotechnology
Language: —
First decided: Mar 4, 2025

Decisions

2025-03-04
Generic application
The Düsseldorf Local Division issued a procedural order in the GlaxoSmithKline v Pfizer RSV vaccine case (EP4183412), deciding to bifurcate by referring the counterclaim for revocation to the Milan Central Division while proceeding with the infringement action, and granting a one-month extension for Pfizer's rejoinder.
Legal issues:Bifurcation (Art. 33(3) UPCA)Referral of counterclaim for revocation to Central DivisionExtension of time period (R.9.3(a) RoP)Procedural efficiency

Documents